Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Adrian BoswoodS G GordonJ HäggströmG WessR L StepienMark A OyamaB W KeeneJ BonaguraK A MacDonaldM PattesonS SmithPhillip R FoxK SandersonR WoolleyViktor SzatmáriP MenautW M ChurchM L O'SullivanJ-P JaudonJ-G KreskenJ RushK A BarrettS L RosenthalA B SaundersI LjungvallM DeinertE BomassiA H EstradaM J Fernandez Del PalacioN S MoiseJonathan A AbbottY FujiiA SpierM W LuethyRoberto A SantilliM UechiA TidholmC SchummerP WatsonPublished in: Journal of veterinary internal medicine (2017)
Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo.